SCM
CAPR icon

Soleus Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Soleus Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-646,390
Closed -$18.7M – 98
2025
Q4 		$18.7M Buy
+646,390
New +$8.44M 0.69% 41

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Soleus Capital Management's CAPR Position: Q1 2026 in Review

Soleus Capital Management sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 646,390 shares — an estimated $18.7M sold.

Soleus Capital Management first reported a position in CAPR in Q4 2025 and held it in 1 quarter. The position peaked at $18.7M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Soleus Capital Management reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Soleus Capital Management sold 646,390 Capricor Therapeutics shares in Q1 2026, an estimated $18.7M.
  • Soleus Capital Management first reported a position in Capricor Therapeutics in Q4 2025 and held it in 1 quarter.
  • Soleus Capital Management's Capricor Therapeutics position peaked at $18.7M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.